423 related articles for article (PubMed ID: 34715057)
1. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
2. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
6. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
8. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
Youn Y; Kim J; Hong YM; Sohn S
Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
Wang L; He M; Wang W; Li S; Zhao G
Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.
Jaggi P; Wang W; Dvorchik I; Printz B; Berry E; Kovalchin JP; Texter K; Ramilo O; Burns JC; Tremoulet AH
Pediatr Infect Dis J; 2015 Dec; 34(12):1315-8. PubMed ID: 26353031
[TBL] [Abstract][Full Text] [Related]
11. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
[TBL] [Abstract][Full Text] [Related]
12. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
Fukui S; Seki M; Minami T; Kotani K; Oka K; Yokomizo A; Matsubara D; Sato T; Nozaki Y; Saito M; Kikuchi Y; Miyamoto K; Monden Y; Yamagata T
Pediatr Rheumatol Online J; 2021 Jul; 19(1):107. PubMed ID: 34217297
[TBL] [Abstract][Full Text] [Related]
14. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H; Suzuki H; Onouchi Y; Ebata R; Terai M; Fuse S; Okajima Y; Kurotobi S; Hirai K; Soga T; Ishiguchi Y; Okuma Y; Takada N; Yanai M; Sato J; Nakayashiro M; Ayusawa M; Yamamoto E; Nomura Y; Hashimura Y; Ouchi K; Masuda H; Takatsuki S; Hirono K; Ariga T; Higaki T; Otsuki A; Terauchi M; Aoyagi R; Sato T; Fujii Y; Fujiwara T; Hanaoka H; Hata A;
Lancet; 2019 Mar; 393(10176):1128-1137. PubMed ID: 30853151
[TBL] [Abstract][Full Text] [Related]
16. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
17. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
19. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.
Yang J; Jain S; Capparelli EV; Best BM; Son MB; Baker A; Newburger JW; Franco A; Printz BF; He F; Shimizu C; Hoshino S; Bainto E; Moreno E; Pancheri J; Burns JC; Tremoulet AH
J Pediatr; 2022 Apr; 243():173-180.e8. PubMed ID: 34953816
[TBL] [Abstract][Full Text] [Related]
20. Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.
Xue LJ; Wu R; Du GL; Xu Y; Yuan KY; Feng ZC; Pan YL; Hu GY
Clin Rev Allergy Immunol; 2017 Jun; 52(3):389-400. PubMed ID: 27550227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
